Marshall Wace, LLP Marker Therapeutics, Inc. Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.37 - $1.0 $45,686 - $123,478	-123,478 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.95 - $1.72 $44,872 - $81,242	-47,234 Reduced 27.67%	123,478 $117,000
Q3 2021 Nov 15, 2021	SELL	$1.68 - $2.88 $263,951 - $452,488	-157,114 Reduced 47.93%	170,712 $289,000
Q2 2021 Aug 13, 2021	BUY	$1.88 - $3.56 $616,312 - $1.17 Million	327,826 New	327,826 $915,000
Q1 2020 May 15, 2020	SELL	$1.59 - $3.35 $222,261 - $468,286	-139,787 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$2.68 - $4.85 $57,922 - $104,823	-21,613 Reduced 13.39%	139,787 $403,000
Q3 2019 Nov 14, 2019	BUY	$4.1 - $9.0 $661,740 - $1.45 Million	161,400 New	161,400 $825,000

475K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $269M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.